GCM
BIIB icon

Graham Capital Management’s Biogen BIIB Stock Holding History

Graham Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,342
Closed -$1.9M – 1263
2026
Q1 		$1.9M Buy
+10,342
New +$1.91M 0.05% 300
2025
Q1 		– Sell
-13,357
Closed -$2.04M – 1298
2024
Q4 		$2.04M Buy
+13,357
New +$2.25M 0.03% 284
2022
Q3 		– Sell
-1,580
Closed -$322K – 1069
2022
Q2 		$322K Sell
1,580
-2,541
-62% -$519K 0.01% 803
2022
Q1 		$867K Buy
+4,121
New +$896K 0.03% 360
2015
Q4 		– Sell
-21,071
Closed -$6.15M – 55
2015
Q3 		$6.15M Buy
21,071
+19,921
+1,732% +$6.58M 0.74% 40
2015
Q2 		$465K Buy
+1,150
New +$462K 0.03% 109

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's BIIB Position: Q2 2026 in Review

Graham Capital Management sold out of Biogen (BIIB) in Q2 2026, closing a stake of 10,342 shares — an estimated $1.9M sold.

Graham Capital Management first reported a position in BIIB in Q2 2015 and held it in 6 quarters. The position peaked at $6.15M in Q3 2015. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Graham Capital Management reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 10,342 Biogen shares in Q2 2026, an estimated $1.9M.
  • Graham Capital Management first reported a position in Biogen in Q2 2015 and held it in 6 quarters.
  • Graham Capital Management's Biogen position peaked at $6.15M in Q3 2015.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.